Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Deep Vein Thrombosis (DVT)-Pipeline Review, H1 2015

Deep Vein Thrombosis (DVT)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Deep Vein Thrombosis (DVT)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Deep Vein Thrombosis (DVT)-Pipeline Review, H1 2015', provides an overview of the Deep Vein Thrombosis (DVT)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis (DVT)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Deep Vein Thrombosis (DVT) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Deep Vein Thrombosis (DVT) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Deep Vein Thrombosis (DVT) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Deep Vein Thrombosis (DVT)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Deep Vein Thrombosis (DVT) Overview 7

Therapeutics Development 8

Pipeline Products for Deep Vein Thrombosis (DVT)-Overview 8

Pipeline Products for Deep Vein Thrombosis (DVT)-Comparative Analysis 9

Deep Vein Thrombosis (DVT)-Therapeutics under Development by Companies 10

Deep Vein Thrombosis (DVT)-Therapeutics under Investigation by Universities/Institutes 11

Deep Vein Thrombosis (DVT)-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Deep Vein Thrombosis (DVT)-Products under Development by Companies 15

Deep Vein Thrombosis (DVT)-Products under Investigation by Universities/Institutes 16

Deep Vein Thrombosis (DVT)-Companies Involved in Therapeutics Development 17

Bayer AG 17

Bristol-Myers Squibb Company 18

F. Hoffmann-La Roche Ltd. 19

Generex Biotechnology Corporation 20

Laboratorios Farmaceuticos Rovi, S.A. 21

Merrion Pharmaceuticals Plc 22

Tobira Therapeutics, Inc. 23

Deep Vein Thrombosis (DVT)-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

apixaban-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

enoxaparin biosimilar-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

enoxaparin sodium-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

fondaparinux sodium-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

REG-2-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

rivaroxaban-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

RNAi Oligonucleotide for DVT-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Small Molecules for Hematological Disorders and Cancer-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

TRX-1-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Deep Vein Thrombosis (DVT)-Recent Pipeline Updates 48

Deep Vein Thrombosis (DVT)-Dormant Projects 66

Deep Vein Thrombosis (DVT)-Discontinued Products 67

Deep Vein Thrombosis (DVT)-Product Development Milestones 68

Featured News & Press Releases 68

May 04, 2015: Bayer's Xarelto Approved in China for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and for the Treatment of Deep Vein Thrombosis 68

Apr 07, 2015: Xarelto Litigation Update: Legal-Bay Lawsuit Settlement Funding Reports Issuance of New Court Documents 68

Mar 30, 2015: New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO Compared to Traditional Therapy, With No Difference in Subsequent Hospital Visits 69

Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO 71

Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE 72

Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy 73

Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 74

Jun 27, 2014: Eliquis (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 76

Mar 14, 2014: U.S. FDA Approves Eliquis (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery 77

Dec 19, 2013: FDA Accepts For Review ELIQUIS Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis And Pulmonary Embolism, And For The Reduction In The Risk Of Recurrent DVT And PE 78

Appendix 79

Methodology 79

Coverage 79

Secondary Research 79

Primary Research 79

Expert Panel Validation 79

Contact Us 79

Disclaimer 80

List of Tables

Number of Products under Development for Deep Vein Thrombosis (DVT), H1 2015 8

Number of Products under Development for Deep Vein Thrombosis (DVT)-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Investigation by Universities/Institutes, H1 2015 16

Deep Vein Thrombosis (DVT)-Pipeline by Bayer AG, H1 2015 17

Deep Vein Thrombosis (DVT)-Pipeline by Bristol-Myers Squibb Company, H1 2015 18

Deep Vein Thrombosis (DVT)-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 19

Deep Vein Thrombosis (DVT)-Pipeline by Generex Biotechnology Corporation, H1 2015 20

Deep Vein Thrombosis (DVT)-Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H1 2015 21

Deep Vein Thrombosis (DVT)-Pipeline by Merrion Pharmaceuticals Plc, H1 2015 22

Deep Vein Thrombosis (DVT)-Pipeline by Tobira Therapeutics, Inc., H1 2015 23

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Stage and Target, H1 2015 26

Number of Products by Stage and Mechanism of Action, H1 2015 28

Number of Products by Stage and Route of Administration, H1 2015 30

Number of Products by Stage and Molecule Type, H1 2015 32

Deep Vein Thrombosis (DVT) Therapeutics-Recent Pipeline Updates, H1 2015 48

Deep Vein Thrombosis (DVT)-Dormant Projects, H1 2015 66

Deep Vein Thrombosis (DVT)-Discontinued Products, H1 2015 67

List of Figures

Number of Products under Development for Deep Vein Thrombosis (DVT), H1 2015 8

Number of Products under Development for Deep Vein Thrombosis (DVT)-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Top 10 Targets, H1 2015 25

Number of Products by Stage and Top 10 Targets, H1 2015 26

Number of Products by Top 10 Mechanism of Actions, H1 2015 27

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Top 10 Routes of Administration, H1 2015 29

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30

Number of Products by Top 10 Molecule Types, H1 2015 31

Number of Products by Stage and Top 10 Molecule Types, H1 2015 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bayer AG

Bristol-Myers Squibb Company

F. Hoffmann-La Roche Ltd.

Generex Biotechnology Corporation

Laboratorios Farmaceuticos Rovi, S.A.

Merrion Pharmaceuticals Plc

Tobira Therapeutics, Inc.

Deep Vein Thrombosis (DVT) Therapeutic Products under Development, Key Players in Deep Vein Thrombosis (DVT) Therapeutics, Deep Vein Thrombosis (DVT) Pipeline Overview, Deep Vein Thrombosis (DVT) Pipeline, Deep Vein Thrombosis (DVT) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com